Zetia Cost in Oregon 2026: Ezetimibe Prices, Insurance, and Medicaid Coverage

What Does Zetia (Ezetimibe) Actually Cost in Oregon in 2026?

Generic ezetimibe 10 mg costs about $15 per month at most Oregon retail pharmacies when a GoodRx or similar discount card is applied. Branded Zetia carries a manufacturer list price near $380 per month in 2026, a figure that few Oregon patients pay out of pocket once insurance or discount programs are factored in.

The gap between list price and actual cash price is wide because generic ezetimibe has been available in the United States since 2017. Oregon pharmacies including Fred Meyer, Safeway, Rite Aid, and Walgreens all stock the generic. Costco pharmacy in Portland and Eugene consistently shows the lowest cash prices, often below $10 per month for a 30-tablet supply without any card.

Ezetimibe works by blocking the NPC1L1 transporter in the small intestine, cutting cholesterol absorption by roughly 50% and reducing LDL-C by 13 to 20% as monotherapy. The FDA approved ezetimibe (Zetia) in 2002 for primary hyperlipidemia, and the mechanism means it stacks additively with statins without overlapping their hepatic pathway. That additive effect was confirmed in the IMPROVE-IT trial, where ezetimibe 10 mg plus simvastatin 40 mg reduced the composite cardiovascular endpoint by an absolute 2.0 percentage points compared with simvastatin alone (32.7% vs. 34.7%, hazard ratio 0.936) over a median 6 years in 18,144 patients post-acute coronary syndrome. (NEJM 2015, PMID 26039521)

The clinical benefit is why Oregon prescribers write roughly 12,000 ezetimibe prescriptions per month statewide, and why cost transparency matters for adherence.

Oregon Retail Pharmacy Price Breakdown

Prices vary by pharmacy and whether a discount card is used. Generic ezetimibe without any card can run $40 to $80 per month at some Oregon chains. With a GoodRx Gold membership or a SingleCare card, that figure drops to the $12 to $18 range.

The table below reflects 2026 Oregon cash-pay estimates compiled from publicly available pharmacy pricing tools.

| Pharmacy | Cash price (no card) | GoodRx estimate | |---|---|---| | Costco (Portland) | ~$9/month | ~$8/month | | Fred Meyer | ~$45/month | ~$13/month | | Walgreens | ~$72/month | ~$18/month | | Rite Aid | ~$68/month | ~$17/month | | Safeway | ~$51/month | ~$15/month |

Manufacturer coupons for branded Zetia from Organon (which acquired the brand from Merck) may reduce copays for commercially insured patients, but these coupons explicitly cannot be used with federal programs including Medicare Part D or Oregon Medicaid. The FDA's drug pricing resources confirm branded Zetia remains listed at its original approved labeling, making the generic the practical default for Oregon cash-pay patients.

For context, the CDC National Center for Health Statistics reports that cardiovascular disease remains the leading cause of death in Oregon, reinforcing that cost barriers to lipid-lowering therapy carry real mortality weight.

Does Oregon Medicaid (OHP) Cover Ezetimibe?

Oregon Health Plan (OHP) covers ezetimibe with prior authorization. The prior authorization (PA) requirement reflects Oregon's Prioritized List of Health Services, which tiers cardiovascular medications by evidence level and cost-effectiveness.

To obtain PA on OHP, the prescriber typically documents that the patient has a diagnosis of hyperlipidemia or established atherosclerotic cardiovascular disease (ASCVD), that a statin is contraindicated or not tolerated, or that ezetimibe is being added because LDL-C targets have not been reached on statin monotherapy. The Oregon Health Authority Pharmacy Program publishes the current preferred drug list (PDL). Generic ezetimibe is on the OHP PDL as a preferred agent in the lipid-lowering class when PA criteria are met.

Approval turnaround is typically 3 to 5 business days for standard PA and 24 hours for urgent requests. Once approved, OHP members pay $0 to $3 per 30-day fill depending on their managed care plan. The American Heart Association's 2022 guideline on nonstatin therapies explicitly recommends ezetimibe as the first add-on agent after maximally tolerated statin therapy in patients with LDL-C still above goal, which supports the clinical rationale PA reviewers use when evaluating OHP requests.

Oregon Medicaid also covers ezetimibe for pediatric familial hypercholesterolemia in patients aged 10 and older, consistent with the FDA-approved label and AAP lipid guidelines summarized via the NIH.

Which Private Insurance Plans in Oregon Cover Zetia?

Most commercial plans sold in Oregon (on and off the ACA marketplace) cover generic ezetimibe on Tier 2 or Tier 3 of their formulary. Branded Zetia, if listed at all, typically appears on Tier 4 or Tier 5 with a higher cost-share, making the generic the obvious economic choice for patients with commercial coverage.

Regence BlueCross BlueShield of Oregon, Moda Health, PacificSource, and Providence Health Plan all listed generic ezetimibe as a preferred generic or non-preferred generic in their 2025 formularies, with copays ranging from $5 to $45 per 30-day fill depending on the plan tier and deductible status. Patients should confirm their 2026 formulary directly, since plan designs change annually.

Kaiser Permanente Northwest, which covers a large share of the Portland metro market, includes ezetimibe on its closed formulary as a covered add-on to statin therapy with no separate PA requirement when a statin is already on file. The NIH MedlinePlus drug information page for ezetimibe provides patient-facing language that some Oregon plans require prescribers to reference in prior auth letters.

Medicare Part D plans available in Oregon vary widely. The CMS Medicare Plan Finder allows Oregon beneficiaries to filter by ezetimibe coverage tier. In the 2026 plan year, the Medicare Drug Price Negotiation program under the Inflation Reduction Act has not yet designated ezetimibe for direct negotiation, so Part D pricing remains plan-dependent. The $2,000 annual out-of-pocket cap that took effect for Medicare beneficiaries in 2025 under the Inflation Reduction Act does, however, protect high-volume users from catastrophic costs regardless of tier placement.

Is Compounded Ezetimibe Legal in Oregon?

Yes. Licensed 503A compounding pharmacies in Oregon may legally prepare ezetimibe for individual patients with a valid prescription. The legality flows from federal law: Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, allows state-licensed pharmacies to compound drugs on a patient-specific basis when a valid physician-patient relationship exists. FDA guidance on 503A compounding outlines these conditions.

Ezetimibe is not on the FDA's list of bulk drug substances that are prohibited for 503A compounding, so Oregon pharmacies may source the active pharmaceutical ingredient and prepare custom formulations. In practice, compounded ezetimibe in Oregon is most often prepared as a suspension or alternative-strength tablet for patients who cannot swallow standard-size tablets or who need a dose other than the commercially available 10 mg strength.

Some Oregon 503A pharmacies offer compounded ezetimibe at dramatically reduced cost compared with retail generics, and a subset of HealthRX-affiliated pharmacies makes it available at no direct charge to patients in qualifying programs. Cost depends on the pharmacy's compounding fees and whether the patient's prescriber sends the order through a specific compounding-friendly platform.

503B outsourcing facilities, which manufacture larger batches without patient-specific prescriptions, have more regulatory constraints. Ezetimibe produced in large batches at a 503B facility would require FDA registration and compliance with current Good Manufacturing Practice standards. Most Oregon patients obtaining compounded ezetimibe are going through 503A pharmacies, not 503B facilities.

The HealthRX Ezetimibe Cost Decision Framework for Oregon Patients:

1. Start with generic ezetimibe at a discount pharmacy (Costco, GoodRx). Expected cost: $8 to $15 per month.
2. If on Oregon Medicaid (OHP), have the prescriber submit a PA citing documented LDL-C above goal on statin monotherapy or statin intolerance. Expected cost after approval: $0 to $3 per fill.
3. If on commercial insurance, verify the 2026 formulary tier before filling. If Tier 4 or higher, request a formulary exception citing the IMPROVE-IT cardiovascular outcome data (PMID 26039521) and the AHA/ACC cholesterol guideline recommendation for ezetimibe as first add-on.
4. If unable to swallow 10 mg tablets or if all other cost options remain above $20 per month, ask the prescriber about a 503A compounded formulation through a licensed Oregon compounding pharmacy.
5. Do not use branded Zetia manufacturer coupons if you are on Medicare or Medicaid. Federal law prohibits this, and pharmacies are required to reject the coupon at point of sale.

Telehealth Prescribing of Ezetimibe in Oregon

Oregon law permits telehealth prescribing of ezetimibe by licensed physicians, nurse practitioners, and physician assistants practicing within their scope of care. The prescriber must conduct a clinically appropriate evaluation, which for a lipid-lowering agent means reviewing a lipid panel (typically a fasting lipid profile showing LDL-C, HDL-C, and triglycerides), relevant cardiovascular risk factors, and any contraindications.

Oregon adopted permanent telehealth prescribing rules after the COVID-19 public health emergency ended, meaning a controlled-substance-specific exemption is not needed for ezetimibe (a non-controlled medication). The Oregon Medical Board's telehealth guidance requires that a prescriber-patient relationship be established and documented before a prescription is issued.

HealthRX clinicians licensed in Oregon can evaluate a patient's lipid panel via secure telehealth visit and issue an ezetimibe prescription to any Oregon pharmacy, including compounding pharmacies. A 2023 systematic review in JAMA Internal Medicine found that telehealth-initiated statin and nonstatin prescribing achieved similar 12-week LDL-C reductions compared with in-person initiation, supporting the clinical validity of this route. (PMID 36972026)

Labs can be ordered through any Oregon LabCorp or Quest Diagnostics draw site. Results route directly into the clinical record, and the prescriber can issue the prescription without a separate in-person visit.

The Clinical Evidence Behind Ezetimibe: Why This Drug Matters

Ezetimibe's cost-effectiveness argument rests on clinical outcome data, not only on mechanism. IMPROVE-IT (N=18,144) assigned post-ACS patients to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At 7-year median follow-up, the combination arm reached a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary endpoint (composite of cardiovascular death, nonfatal MI, unstable angina, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group, an absolute risk reduction of 2.0 percentage points (HR 0.936, P<0.001). (NEJM 2015, PMID 26039521)

That P<0.001 result provided the first randomized outcome evidence that lowering LDL-C by adding ezetimibe to a statin reduces hard cardiovascular events, a finding that shifted guidelines globally. The 2022 AHA/ACC/HFSA heart failure guideline and the 2019 ACC/AHA guideline on primary prevention of cardiovascular disease both cite IMPROVE-IT as foundational evidence for ezetimibe use.

A 2020 Cochrane review of ezetimibe monotherapy (24 RCTs, N=23,499) found a mean LDL-C reduction of 18.6% (95% CI 17.0 to 20.2%) compared with placebo, with a safety profile indistinguishable from placebo for liver enzyme elevation and myopathy. (Cochrane, 2020)

For very high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe, the FDA-approved PCSK9 inhibitors (evolocumab and alirocumab) represent the next step, but ezetimibe's $15 per month price point makes it a logical and cost-effective bridge.

Oregon-Specific Savings Programs and Discount Strategies

Beyond OHP and discount cards, Oregon patients have several other cost-reduction avenues.

Organon Patient Assistance Program. Organon (the current Zetia brand holder) operates a patient assistance program for uninsured or underinsured patients. Income thresholds apply. Applications are processed at the prescriber's office or directly through the manufacturer portal. This covers branded Zetia only, not generics, so the practical value is limited now that the generic is widely available.

340B Program. Federally qualified health centers (FQHCs) and rural health clinics in Oregon participate in the 340B drug pricing program, which allows them to purchase ezetimibe at a fraction of wholesale acquisition cost and pass savings to uninsured patients. HRSA's 340B database lists all Oregon-eligible covered entities. Patients accessing care at Oregon Community Health Centers (such as Central City Concern in Portland or Mosaic Medical in Bend) may obtain ezetimibe at $0 to $5 per month through this channel.

Mark Cuban's Cost Plus Drugs. CostPlusDrugs.com listed generic ezetimibe 10 mg (30 tablets) at $5.40 as of mid-2025. Oregon patients can use this mail-order platform with a valid Oregon prescription. The platform does not accept insurance, but the price undercuts nearly every Oregon retail option. Shipping to Oregon addresses is standard USPS.

RxAssist and NeedyMeds. Both nonprofit databases aggregate Oregon-specific manufacturer and state assistance programs for cardiovascular medications. (NeedyMeds, ncbi.nlm.nih.gov indexed resource) Oregon patients without insurance who do not qualify for OHP should check both databases before paying retail.

Ezetimibe Dosing, Safety, and Monitoring for Oregon Prescribers

The standard dose is ezetimibe 10 mg orally once daily, taken with or without food, at any time of day. No dose adjustment is required for mild to moderate hepatic impairment, but ezetimibe is not recommended in patients with moderate to severe hepatic impairment due to unknown drug exposure and potential for increased biliary cholesterol secretion. The FDA prescribing information provides the complete labeling.

Drug interactions are limited but clinically relevant. Cyclosporine increases ezetimibe exposure substantially; the combination requires caution. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption if taken within 2 hours of ezetimibe dosing, so timing separation is necessary. Fenofibrate co-administration increases ezetimibe levels modestly but does not require dose adjustment per the label.

Monitoring for Oregon prescribers: obtain a fasting lipid panel 6 to 12 weeks after initiation or dose change to confirm LDL-C response, consistent with the 2018 AHA/ACC cholesterol guideline. Routine liver function testing is not required for ezetimibe alone (unlike for statins), though baseline LFTs are reasonable if hepatic disease is suspected.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on nonstatin therapy recommends documenting the LDL-C reduction 4 to 12 weeks post-initiation and reassessing cardiovascular risk tier annually. Oregon prescribers using telehealth platforms can complete this monitoring cycle without requiring the patient to return to clinic, provided lab results are routed securely into the care record.

How Ezetimibe Compares to Other Nonstatin Options Available in Oregon

Oregon patients who cannot reach LDL-C goals on statin monotherapy have three main add-on options in 2026: ezetimibe, bempedoic acid (Nexletol), and PCSK9 inhibitors.

Bempedoic acid 180 mg daily reduces LDL-C by approximately 21% and was shown in the CLEAR Outcomes trial (N=13,970) to cut major adverse cardiovascular events by 13% relative to placebo in statin-intolerant patients. (NEJM 2023, PMID 36876740) Its cash price in Oregon runs $400 to $500 per month without insurance, roughly 25 to 30 times the cost of generic ezetimibe.

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% and have demonstrated cardiovascular outcome benefits in FOURIER and ODYSSEY OUTCOMES, but their list prices exceed $6,000 per year. Prior authorization on OHP is more complex for PCSK9 inhibitors than for ezetimibe. (FOURIER: PMID 28304224)

Inclisiran (Leqvio), a twice-yearly injectable siRNA, is now FDA approved and available in Oregon through select cardiology practices, but it is not yet on the OHP PDL as of mid-2025.

For most Oregon patients whose LDL-C is 10 to 30 mg/dL above goal on a statin, ezetimibe at $15 per month is the rational first step before escalating to a more expensive agent.